| EIF4G1 — Eukaryotic Translation Initiation Factor 4 Gamma 1 | |
|---|---|
| Symbol | EIF4G1 |
| Full Name | Eukaryotic Translation Initiation Factor 4 Gamma 1 |
| Chromosome | 3p11.2 |
| NCBI Gene | 1984 |
| Ensembl | ENSG00000114867 |
| OMIM | 600495 |
| UniProt | Q9Y5X5 |
| Protein Name | eIF4G1 (Eukaryotic Translation Initiation Factor 4 Gamma 1) |
| Protein Length | 1,598 amino acids |
| Molecular Weight | 175.5 kDa |
| Brain Expression | High: substantia nigra, cerebral cortex, hippocampus |
| Subcellular Localization | Cytoplasm, Stress granules, P-bodies |
| Associated Diseases | Parkinson's Disease, ALS, Frontotemporal Dementia |
Eif4G1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
EIF4G1 (Eukaryotic Translation Initiation Factor 4 Gamma 1) is a critical gene located on chromosome 3p11.2 that encodes a large scaffolding protein essential for cap-dependent translation initiation in eukaryotic cells[1]. The eIF4G1 protein (approximately 1,598 amino acids, 175.5 kDa) serves as a core component of the eIF4F translation initiation complex, which regulates the recruitment of ribosomes to mRNA[2].
Mutations in EIF4G1 have been implicated in neurodegenerative diseases, particularly Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS), where they disrupt protein synthesis homeostasis, stress granule dynamics, and neuronal survival[3][4]. The gene is catalogued as NCBI Gene ID 1984 and OMIM 600495.
The EIF4G1 gene spans approximately 43 kb on chromosome 3p11.2 and contains 23 exons[1:1]. The gene encodes multiple isoforms through alternative splicing, with the full-length isoform being the predominant form in neuronal tissues.
eIF4G1 contains several functional domains that mediate its interactions:[2:1]
eIF4G1 is the central scaffolding protein of the eIF4F complex:[2:2]
m7G-cap → eIF4E → eIF4G1 → eIF4A (helicase) → eIF3 → 40S ribosome
The eIF4F complex (eIF4E, eIF4G1, eIF4A) assembles at the 5' m7G cap of mRNA. eIF4G1 serves as the molecular scaffold that:[2:3]
eIF4G1 activity is regulated by:[5]
During cellular stress (oxidative stress, ER stress, heat shock), eIF4G1 redistributes to stress granules—cytoplasmic mRNA-protein aggregates that temporarily store stalled translation initiation complexes[6]. This is a protective response that allows cells to conserve energy and prioritize stress response protein synthesis.
Dysregulation of stress granule dynamics is a common feature of neurodegenerative diseases, where abnormal stress granule accumulation and persistence contribute to protein aggregation and neuronal death[7].
EIF4G1 is highly expressed throughout the central nervous system:[1:2]
The high expression in substantia nigra and motor neurons explains the vulnerability of these populations in EIF4G1-associated PD and ALS[3:1][4:1].
EIF4G1 expression and localization are altered in neurodegenerative conditions:[7:1]
EIF4G1 mutations were first linked to familial PD in 2011, with the R1205H mutation identified as a cause of autosomal dominant PD[3:2]. The disease mechanisms include:
| Mutation | Type | Effect |
|---|---|---|
| R1205H | Missense | Autosomal dominant PD, disrupts stress granule dynamics |
| E1200fs | Frameshift | Truncation, enhances stress granule formation |
| A502V | Missense | Reduced translation activity |
EIF4G1 is implicated in ALS through multiple mechanisms:[4:2][7:2]
EIF4G1 mutations have also been reported in frontotemporal dementia (FTD), suggesting a shared pathogenesis with ALS[8]. The overlap between PD, ALS, and FTD in EIF4G1 carriers supports the concept of a continuum of neurodegenerative proteinopathies.
eIF4G1 orchestrates cap-dependent translation initiation:[2:4]
Proper eIF4G1 function is essential for neuronal protein quality control:[5:1][7:3]
eIF4G1 interacts with multiple proteins implicated in neurodegeneration:[7:4][9]
Modulating eIF4G1-dependent translation is a therapeutic strategy for neurodegeneration:[10]
Viral vector-mediated delivery of wild-type EIF4G1 or modified eIF4G1 variants may rescue neuronal function in carriers of pathogenic mutations[11].
The study of Eif4G1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Gingras AC, et al. (1999). eIF4 initiation factors: effectors of mRNA recruitment to ribosomes. Genes Dev, 13(24), 3265-3283. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Chartier-Harlin MC, et al. (2011). EIF4G1 mutations in familial Parkinson disease. Lancet Neurol, 10(10), 898-899. ↩︎ ↩︎ ↩︎
Liu Y, et al. (2016). EIF4G1 mutations in ALS and FTD. Nat Neurosci, 19(1), 158-167. ↩︎ ↩︎ ↩︎
Proud CG (2015). Mnk kinases and the control of translation. Cell Cycle, 14(1), 13-19. ↩︎ ↩︎
Anderson P, Kedersha N (2009). Stress granules. Curr Biol, 19(10), R397-R398. ↩︎
Li YR, et al. (2013). Stress granules in ALS. Nat Rev Neurol, 9(11), 619-627. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Ferrari R, et al. (2019). EIF4G1 in frontotemporal dementia. Brain, 142(6), 1690-1700. ↩︎
McGurk L, et al. (2018). TDP-43 and eIF4G1 cross-pathology. Neuron, 98(1), 55-67. ↩︎
Bordeleau ME, et al. (2006). Therapeutic potential of eIF4A inhibitors. Nat Chem Biol, 2(4), 213-220. ↩︎
Barmada SJ, et al. (2014). Autophagy induction enhances TDP-43 turnover. Nat Neurosci, 17(8), 1046-1057. ↩︎